HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program
HCW Biologics (NASDAQ: HCWB), a clinical-stage biopharmaceutical company, presented its second-generation T-Cell Engager (TCE) program in a Virtual Investor segment. Chief Scientific Officer Dr. Peter Rhode discussed the company's recent advancements in their TCE technology.
The company's improved TCE program demonstrates enhanced manufacturability, safety profile, and effectiveness against solid tumors. These second-generation TCEs aim to address key limitations of first-generation treatments, including complex manufacturing, tolerability issues, and limited efficacy for solid tumors. HCW Biologics has positioned itself among select biotech companies developing innovative TCEs that can overcome resistance mechanisms.
HCW Biologics (NASDAQ: HCWB), una società biofarmaceutica in fase clinica, ha presentato il suo programma di T-Cell Engager (TCE) di seconda generazione in un segmento Virtual Investor. Il Direttore Scientifico Dr. Peter Rhode ha illustrato i recenti progressi della tecnologia TCE dell'azienda.
Il programma TCE migliorato dell'azienda mostra una maggiore fattibilità di produzione, profilo di sicurezza potenziato ed efficacia contro tumori solidi. Questi TCE di seconda generazione mirano a superare i principali limiti dei trattamenti di prima generazione, tra cui la produzione complessa, problemi di tollerabilità e efficacia limitata sui tumori solidi. HCW Biologics si posiziona tra le poche aziende biotech che sviluppano TCE innovativi in grado di superare i meccanismi di resistenza.
HCW Biologics (NASDAQ: HCWB), una compañía biofarmacéutica en etapa clínica, presentó su programa de T-Cell Engager (TCE) de segunda generación en un segmento de Inversores Virtuales. El Director Científico Dr. Peter Rhode discutió los avances recientes de la tecnología TCE de la empresa.
El programa TCE mejorado de la empresa demuestra una mayor factibilidad de fabricación, perfil de seguridad mejorado y mayor eficacia contra tumores sólidos. Estos TCE de segunda generación buscan abordar las limitaciones clave de los tratamientos de primera generación, incluyendo la fabricación compleja, problemas de tolerancia y eficacia limitada para tumores sólidos. HCW Biologics se ha posicionado entre un selecto grupo de empresas biotecnológicas que desarrollan TCE innovadores capaces de superar mecanismos de resistencia.
HCW Biologics(나스닥: HCWB)는 임상 단계의 생물의약품 회사로, 가상 투자자 세그먼트에서 두 번째 세대 T-세포 엔게저(TCE) 프로그램을 발표했습니다. 최고과학책임자 Dr. Peter Rhode가 회사의 TCE 기술의 최근 발전을 논의했습니다.
회사의 개선된 TCE 프로그램은 향상된 제조 가능성, 안전성 프로파일 및 고형 암종에 대한 효과을 보여줍니다. 이 2세대 TCE는 제조의 복잡성, 내약성 문제, 고형 암종에 대한 한정된 효능 등 1세대 치료의 주요 한계점을 해결하는 것을 목표로 합니다. HCW Biologics는 저항 기전을 극복할 수 있는 혁신적인 TCE를 개발하는 일부 생명공학 회사들 사이에 자리를 잡았습니다.
HCW Biologics (NASDAQ: HCWB), une société biopharmaceutique en phase clinique, a présenté son programme T-Cell Engager (TCE) de seconde génération lors d'un segment Virtual Investor. Le Dr Peter Rhode, directeur scientifique, a discuté des avancées récentes de la technologie TCE de l'entreprise.
Le programme TCE amélioré de l'entreprise démontre une meilleure fabriquabilité, un profil de sécurité optimisé et une efficacité accrue contre les tumeurs solides. Ces TCE de seconde génération visent à surmonter les limitations clés des traitements de première génération, notamment la fabrication complexe, les problèmes de tolérance et l'efficacité limitée contre les tumeurs solides. HCW Biologics s'est positionnée parmi les sociétés biotechnologiques qui développent des TCE innovants capables de contourner les mécanismes de résistance.
HCW Biologics (NASDAQ: HCWB), ein klinisch entwickeltes Biopharmaunternehmen, stellte sein T-Cell Engager (TCE)-Programm der zweiten Generation in einem Virtual-Investor-Segment vor. Der Chief Scientific Officer Dr. Peter Rhode erläuterte die jüngsten Fortschritte des TCE-Technologie des Unternehmens.
Das verbesserte TCE-Programm des Unternehmens zeigt eine verbesserte Herstellbarkeit, ein besseres Sicherheitsprofil und eine höhere Wirksamkeit gegen solide Tumore. Diese TCEs der zweiten Generation zielen darauf ab, zentrale Limitierungen der Erstgeneration-Behandlungen zu adressieren, darunter komplexe Herstellung, Verträglichkeitssprobleme und begrenzte Wirksamkeit bei soliden Tumoren. HCW Biologics positioniert sich unter ausgewählten Biotech-Unternehmen, die innovative TCEs entwickeln, die Resistenzen überwinden können.
HCW Biologics (بورصة ناسداك: HCWB)، شركة أدوية حيوية في مرحلة إكلينيكية، قدمت برنامجها من الجيل الثاني من مُنجِّهِ الخلية التائية (TCE) في فقرة مستثمرين افتراضيين. ناقش الدكتور بيتر رود، كبار العلماء، التقدمات الأخيرة في تكنولوجيا TCE لدى الشركة.
يظهر البرنامج المحسَّن لـ TCE لدى الشركة قابلية تصنيع محسّنة، وملف أمان محسن، وفعالية أعلى ضد الأورام الصلبة. تهدف هذه الـ TCEs من الجيل الثاني إلى معالجة القيود الأساسية لعلاجات الجيل الأول، بما في ذلك التصنيع المعقد، مشاكل التحمل، وفعالية محدودة ضد الأورام الصلبة. لقد وضعت HCW Biologics نفسها بين شركات التكنولوجيا الحيوية المختارة التي تطور TCE مبتكرة يمكنها التغلب على آليات المقاومة.
HCW Biologics (纳斯达克股票代码: HCWB)，一家处于临床阶段的生物制药公司，在一个虚拟投资者环节中展示了其第二代 T 细胞识别程序（TCE）。首席科学官彼得·罗德博士讨论了公司在 TCE 技术方面的最新进展。
公司改进的 TCE 计划显示出提高的可制造性、安全性特征和对实体瘤的有效性。这些第二代 TCE 旨在解决第一代治疗的关键局限，包括制造复杂性、耐受性问题以及对实体瘤的有限疗效。HCW Biologics 已在开发能克服抗性机制的创新性 TCE 的少数生物科技公司中占据一席之地。
- Development of improved second-generation T-Cell Engager program with better manufacturability
- Positive safety profile demonstrated in non-human primate study
- Enhanced capability to treat solid tumors compared to first-generation TCEs
- None.
Watch the "What This Means" video here
Featuring Company’s second-generation T-Cell Engager program
and advantages over first-generation
Company’s T-Cell Engager program has made improvements in manufacturability, preclinical safety profile, and ability to treat a wide spectrum of solid tumors
MIRAMAR, Fla., Sept. 30, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics, participated in a Virtual Investor “What This Means” segment.
As part of the segment, Dr. Rhode discussed the Company’s recent news announcing its TRBC-based second-generation T-Cell Engager (“TCE”) program and the positive safety profile from a non-human primate investigative study recently conducted by the Company for its TCE program. HCW Biologics believes its second-generation TCEs could alleviate the challenges of the first generation TCEs, such as complex manufacturing processes, tolerability, safety, antigen selection, and efficacy for solid tumors. The Company has joined a small group of innovative biotechnology companies who have discovered new TCEs that overcome resistance mechanisms and improve the ability to treat solid tumors.
The Virtual Investor “What This Means” segment featuring HCW Biologics is now available here.
About HCW Biologics:
HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients’ quality of life and potentially extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as many indications that impact quality-of-life that are not life-threatening. The Company’s lead product candidate, HCW9302, was developed using the Company’s legacy TOBI™ (Tissue factOr-Based fusIon) platform. The Company has created another drug discovery technology, the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers. These novel immunotherapeutics are being developed for treatment of a wide range of disease indications, including oncology, autoimmune diseases, and improving quality of life conditions. The Company has constructed over 50 molecules using the TRBC platform. Further preclinical evaluation studies are currently being conducted for these molecules the Company has selected based on promising preclinical data. The Company has two licensing programs in which it has licensed exclusive rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/
Forward Looking Statements:
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words and include, the actual success and potency of the Company’s TCE-based TRBC fusion molecules; the ability of the Company’s TCE’s to target cancer antigens, CD3 activation of effector T cells, and reduce immunosuppression in the tumor microenvironment; the ability of the Company’s TCEs to exhibit potent and antigen-specific anti-pancreatic cancer activities both in vitro and in humanized mouse models; or whether the Company’s TCEs are effective in treatment of solid tumors and pancreatic cancers. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 28, 2025, the latest Form 10-Q filed with the SEC on August 18, 2025 and in other filings filed from time to time with the SEC.
Company Contact:
Dr. Peter Rhode
Chief Scientific Officer and Vice President of Clinical Operations
HCW Biologics Inc.
PeterRhode@HCWBiologics.com
FAQ
What improvements does HCW Biologics' second-generation T-Cell Engager program offer?
What are the key challenges that HCWB's new T-Cell Engager program addresses?
Who presented HCWB's T-Cell Engager program developments in the Virtual Investor segment?
What was the outcome of HCWB's non-human primate study for their TCE program?
What is HCW Biologics' main focus as a company?
